Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L; DeLLphi-301 Investigators. Ahn MJ, et al. N Engl J Med. 2023 Nov 30;389(22):2063-2075. doi: 10.1056/NEJMoa2307980. Epub 2023 Oct 20. N Engl J Med. 2023. PMID: 37861218 Clinical Trial.
Accelerated subsequent lung cancer after post-operative radiotherapy for breast cancer.
Basse C, Ancel J, Massiani MA, Bonté PE, Beaulaton C, Beaucaire-Danel S, Milder M, Cao K, Daniel C, Du Rusquec P, Sablin MP, Kirova Y, Sage E, Beddok A, Girard N. Basse C, et al. Among authors: du rusquec p. Lung Cancer. 2023 Aug;182:107295. doi: 10.1016/j.lungcan.2023.107295. Epub 2023 Jul 11. Lung Cancer. 2023. PMID: 37442059
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.
Thomas QD, Quantin X, Lemercier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Perol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Hiret S, Clement-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P. Thomas QD, et al. Among authors: du rusquec p. ESMO Open. 2024 Jun;9(6):103473. doi: 10.1016/j.esmoop.2024.103473. Epub 2024 Jun 3. ESMO Open. 2024. PMID: 38833966 Free PMC article.
Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy.
Huet C, Basse C, Knetki-Wroblewska M, Chilczuk P, Bonte PE, Cyrille S, Gobbini E, Du Rusquec P, Olszyna-Serementa M, Daniel C, Lucibello F, Lahmi L, Krzakowski M, Girard N. Huet C, et al. Among authors: du rusquec p. Clin Lung Cancer. 2024 Dec;25(8):e402-e410.e3. doi: 10.1016/j.cllc.2024.07.009. Epub 2024 Aug 8. Clin Lung Cancer. 2024. PMID: 39214846
Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
Ferreira M, Swalduz A, Greillier L, du Rusquec P, Curcio H, Raimbourg J, Toffart AC, Gounant V, Couraud S, De Chabot G, Friard S, Hureaux J, Jeannin G, Odier L, Ricordel C, Wislez M, Descarpentries C, Herbreteau G, Missy P, Morin F, Westeel V, Cortot AB. Ferreira M, et al. Among authors: du rusquec p. Lung Cancer. 2024 Oct;196:107934. doi: 10.1016/j.lungcan.2024.107934. Epub 2024 Aug 24. Lung Cancer. 2024. PMID: 39277916 Clinical Trial.
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study.
Manson G, Maria ATJ, Poizeau F, Danlos FX, Kostine M, Brosseau S, Aspeslagh S, Du Rusquec P, Roger M, Pallix-Guyot M, Ruivard M, Dousset L, Grignou L, Psimaras D, Pluvy J, Quéré G, Grados F, Duval F, Bourdain F, Maigne G, Perrin J, Godbert B, Taifas BI, Forestier A, Voisin AL, Martin-Romano P, Baldini C, Marabelle A, Massard C, Honnorat J, Lambotte O, Michot JM. Manson G, et al. Among authors: du rusquec p. J Immunother Cancer. 2019 Dec 3;7(1):337. doi: 10.1186/s40425-019-0821-8. J Immunother Cancer. 2019. PMID: 31796119 Free PMC article.
Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.
du Rusquec P, Guimbaud R, Le Malicot K, Gornet JM, Nguyen S, Lecomte T, Khemissa-Akouz F, Perrier H, Bouché O, Paoletti X, Le Tourneau C. du Rusquec P, et al. ESMO Open. 2023 Aug;8(4):101616. doi: 10.1016/j.esmoop.2023.101616. Epub 2023 Aug 4. ESMO Open. 2023. PMID: 37542912 Free PMC article. Clinical Trial.
27 results